Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males
Phase 2
Terminated
- Conditions
- Neisseria Gonorrhoeae
- Interventions
- Drug: 1 mg/kg single infusion of F598Drug: 3 mg/kg single infusion of F598Drug: 10 mg/kg single infusion of F598
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Alopexx Pharmaceuticals, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03222401
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
News
Alopexx Secures Investment from Biotech Consortia to Advance Broad-Spectrum Antimicrobial Vaccine AV0328
Alopexx, Inc. has received investment from Biotech Consortia, Inc. to support the development and commercialization of its antimicrobial vaccine, AV0328.